Duyuru • Feb 17
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 26, 2026, at 12:00 W. Europe Standard Time. Duyuru • Feb 07
Sartorius Aktiengesellschaft announces Annual dividend, payable on March 31, 2026 Sartorius Aktiengesellschaft announced Annual dividend of EUR 0.7400 per share payable on March 31, 2026, ex-date on March 27, 2026 and record date on March 30, 2026. Duyuru • Feb 05
Sartorius AG Provides Earnings Guidance for the Fiscal Year 2026 Sartorius AG provided earnings guidance for the fiscal year 2026. For the year, the company expects its profitable growth trajectory to continue, with a continued positive development in the Bioprocess Solutions Division and a recovery in the Lab Products & Services Division. Duyuru • Jan 28
Sartorius Aktiengesellschaft to Report Fiscal Year 2025 Final Results on Feb 16, 2026 Sartorius Aktiengesellschaft announced that they will report fiscal year 2025 final results at 12:00 PM, Central European Standard Time on Feb 16, 2026 Duyuru • Jan 16
Sartorius Expands Bio-Circular Product Offering for More Sustainable Bioprocesses Sartorius AG expanded bio-circular product offering for more sustainable bioprocesses. Further production hubs in Germany and Tunisia now certified by International Sustainability and Carbon Certification. Certified raw materials significantly reduce dependence on fossil-based plastics. Bio-circular filters and additional single-use fluid management technologies now available for biopharma manufacturers. Certified production network spans sites in Germany, Tunisia, France and the UK. With ISCC Plus certification now extended to its sites in Gottingen, Germany, and M'Hamdia, Tunisia, the company can use certified renewable raw materials in additional product lines, reducing the share of fossil-based plastics while ensuring full compatibility with existing bioprocesses. ISCC Plus is a global standard for renewable and recycled raw materials that ensures transparent and traceable sourcing and compliance across the value chain based on a mass-balance system. At its Gottingen headquarters, Sartorius will produce the PFAS-free filter Sartopore Evo using ISCC Plus-certified materials. In M'Hamdia, selected Flexsafe bags will be manufactured with certified second generation feedstock. The use of ISCC Plus-certified material enables a reduction of fossil-based compounds by around 70% in the Flexsafe film and by an average 40-60% in Sartopore Evo filters. Earlier in 2025, Sartorius achieved ISCC Plus certification for its sites in Aubagne, France, and Stonehouse, United Kingdom, covering its Ambr bioreactor vessels, Vivaflow filters, and selected Flexsafe bags for the manufacture of biopharmaceutical. The company plans to expand the use of certified renewable raw materials across its global production network. Duyuru • Oct 17
Sartorius Aktiengesellschaft Revises Financial Guidance for the Year 2025 Sartorius Aktiengesellschaft revised financial guidance for the year 2025. Based on the year-to-date results and taking into account the anticipated impact of existing tariffs, the contributions from the MATTEK acquisition, as well as the strong basis for comparison in the fourth quarter of 2024, management further sharpens its full-year guidance for the Group and both divisions. The company now expects sales revenue growth at Group level of around 7% (previously: around 6% organic growth with a forecast range of about plus/minus two percentage points). This includes an inorganic growth contribution of around 0.3%. Duyuru • Apr 17
Sartorius Aktiengesellschaft Provides Earnings Guidance for the Fiscal 2025 Sartorius Aktiengesellschaft provided earnings guidance for the fiscal 2025. For the period, Based on the first quarter results and the expected good underlying market development, management projects sales revenue growth of around 6% for the Group, around 7% for the Bioprocess Solutions division and around 1% for Lab Products & Services for 2025. Due to the continued above-average volatility, the company currently anticipates a forecast range of about plus/minus two percentage points respectively. Duyuru • Mar 29
Sartorius Ag Approves Ordinary Dividend, Payable on April 1, 2025 Sartorius AG at its AGM held on March 27, 2025, approved the dividend of 0.73 euros per ordinary share. The total amount disbursed will be 50.7 million euros, with the dividend to be paid out to shareholders on April 1, 2025. Duyuru • Feb 18
Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025 Sartorius Aktiengesellschaft, Annual General Meeting, Mar 27, 2025. Duyuru • Feb 09
Sartorius AG Proposes Ordinary Dividend for Fiscal 2024, Payable on April 1, 2025 The Supervisory Board of Sartorius AG resolved at its meeting held on February 7, 2025 to approve the recommendation of the Executive Board to submit a proposal to the Annual General Meeting on March 27, 2025, to pay a dividend of EUR 0.73 per ordinary share for fiscal 2024, the same amount as for the previous year. The dividend will be paid on April 1, 2025. Duyuru • Nov 16
Sartorius Aktiengesellschaft to Report Fiscal Year 2024 Results on Jan 28, 2025 Sartorius Aktiengesellschaft announced that they will report fiscal year 2024 results on Jan 28, 2025 Duyuru • Sep 19
Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3). Labforward GmbH acquired LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Sartorius will become a shareholder in labforward GmbH post the transaction. The merged company will be led by Joerg Hoffmann of labforward GmbH. The future headquarters will be the previous location of LabTwin in Berlin.
Labforward GmbH completed the acquisition of LabTwin GmbH from Sartorius Aktiengesellschaft (XTRA:SRT3) on September 17, 2024. Reported Earnings • Apr 19
First quarter 2024 earnings released First quarter 2024 results: Revenue: €819.6m (down 9.3% from 1Q 2023). Net income: €36.7m (down 61% from 1Q 2023). Profit margin: 4.5% (down from 10% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Declared Dividend • Mar 25
Dividend of €0.74 announced Shareholders will receive a dividend of €0.74. Ex-date: 2nd April 2024 Payment date: 4th April 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.5%. Payout Ratios Payout ratio: 25%. Cash payout ratio: 17%. Duyuru • Feb 03
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Final Results on Feb 16, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 final results at 7:00 AM, Central European Standard Time on Feb 16, 2024 Duyuru • Jan 18
Sartorius Aktiengesellschaft to Report Fiscal Year 2023 Results on Jan 26, 2024 Sartorius Aktiengesellschaft announced that they will report fiscal year 2023 results at 7:00 AM, Central European Standard Time on Jan 26, 2024 Reported Earnings • Oct 21
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €810.7m (down 23% from 3Q 2022). Net income: €8.60m (down 94% from 3Q 2022). Profit margin: 1.1% (down from 15% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Life Sciences industry in the United Kingdom. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €265, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 30% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €259 per share. Duyuru • Oct 13
Sartorius Ag Lowers Earnings Forecast for the Fiscal Year 2023 SARTORIUS AG lowered earnings forecast for the fiscal year 2023. For the year, Group sales revenue is expected to decline by around 17 percent; excluding Covid-19-related business, revenue would decline by around 12% (previously: sales revenue decline in the low to mid-teens percentage range; excluding Covid-19-related business, decline in the mid to high single-digit percentage range). Acquisitions are still expected to contribute around 2 percentage points to the sales revenue development. Reported Earnings • Jul 26
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €832.0m (down 20% from 2Q 2022). Net income: €95.0m (down 43% from 2Q 2022). Profit margin: 11% (down from 16% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. New Risk • Jun 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Share price has been volatile over the past 3 months (7.7% average weekly change). Reported Earnings • Apr 23
First quarter 2023 earnings released First quarter 2023 results: EPS: €1.36. Revenue: €903.2m (down 12% from 1Q 2022). Net income: €93.1m (down 55% from 1Q 2022). Profit margin: 10% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Life Sciences industry in the United Kingdom. Upcoming Dividend • Mar 23
Upcoming dividend of €1.44 per share at 0.4% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 03 April 2023. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of British dividend payers (5.7%). Lower than average of industry peers (0.7%). Duyuru • Jan 27
Sartorius Aktiengesellschaft Provides Revenue Guidance for the Full Year 2023 Sartorius Aktiengesellschaft provided revenue guidance for the full year 2023. Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. Excluding the Covid-19-related business, the increase would be in the high single-digit percentage range. Acquisitions are anticipated to contribute around 1% point to growth. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment improved over the past week After last week's 16% share price gain to €415, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 35x in the Life Sciences industry in Europe. Total returns to shareholders of 93% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €222 per share. Duyuru • Jan 04
Sartorius Announces Management Changes for Sartorius North America Sartorius announced Maurice Phelan has assumed the role of President of Sartorius North America. He succeeds Mary Lavin, who has retired after nearly 35 years. Sartorius North America, headquartered in Bohemia, New York, currently employs more than 3,000 employees across 17 sites in the United States and Canada. Mr. Phelan has spent many years in the industry and recently rejoined Sartorius from Repligen, where he was Vice President of Fluid Management. Before that, he served as Head of Operations of the Sartorius site in Marlborough, Massachusetts. Previously, he held leadership roles at GE Healthcare and Merck Millipore. Mr. Phelan holds degrees in chemistry and experimental physics from the National University of Ireland. Duyuru • Oct 20
Sartorius Aktiengesellschaft to Report Fiscal Year 2022 Final Results on Feb 17, 2023 Sartorius Aktiengesellschaft announced that they will report fiscal year 2022 final results on Feb 17, 2023 Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment improved over the past week After last week's 15% share price gain to €398, the stock trades at a forward P/E ratio of 43x. Average forward P/E is 33x in the Life Sciences industry in Europe. Total returns to shareholders of 150% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €239 per share.